← Back to search
VAXCYTE, INC.
Doing business as VAXCYTE INC
SAN CARLOS, CA, 94070
UnclaimedClaim this profile (free)
Subcontracting experience
2 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | GROUP A STREPTOCOCCUS OR GAS (STREPTOCOCCUS PYOGENES) IS A HUMAN PATHOGEN CAUSING 700 MILLION CASES OF PHARYNGITIS (€ˌSTREP THROAT€„¢) ANNUALLY WORLDWIDE WHILE CDC ESTIMATES APPROXIMATELY 11,000 TO 13,000 CASES OF INVASIVE GAS DISEASE OCCUR EACH YEAR IN THE UNITED STATES ALONE FROM WHICH, BETWEEN 1,100 AND 1,600 PEOPLE DIE. OVERALL, €ˌSTREP THROAT€„¢ IS HIGHLY PREVALENT IN SCHOOL-AGE CHILDREN AND A SIGNIFICANT SOURCE OF ANTIBIOTIC PRESCRIPTION WORLDWIDE, DRIVING SELECTIVE PRESSURE FOR RESISTANCE THROUGHOUT THE HUMAN MICROFLORA. FURTHERMORE, GAS IS ALSO RESPONSIBLE FOR POST-INFECTIOUS IMMUNE-MEDIATED RHEUMATIC HEART DISEASE (RHD), A LEADING CAUSE OF MORTALITY IN THE DEVELOPING WORLD. SOME 30 MILLION PEOPLE ARE CURRENTLY AFFECTED BY RHD, WITH OVER 420,000 DEATHS ANNUALLY (60% < AGE 70) AND 11.5 MILLION DISABILITY-ADJUSTED LIFE YEARS LOST. DESPITE THE HIGH GLOBAL DEMAND, THERE IS NO SAFE AND EFFECTIVE VACCINE AGAINST GAS. THE WORLD HEALTH ORGANIZATION, INTERNATIONAL VACCINE INSTITUTE, WELLCOME TRUST, GATES FOUNDATION, AND OTHERS HAVE CONVENED ADVISORIES ON GAS VACCINE DEVELOPMENT TO ADDRESS THESE SIGNIFICANT SCIENTIFIC CHALLENGES AND MEET THIS PARAMOUNT GLOBAL HEALTH NEED.
TO ACHIEVE THIS GOAL AND TO GENERATE A SAFE, ECONOMICAL AND EFFECTIVE VACCINE AGAINST GAS INFECTIONS, THE TEAMS AT VAXCYTE AND NIZET LAB (UCSD) ARE COLLABORATING TO UTILIZE THEIR TECHNOLOGICAL EXPERTISE TO DEVELOP A UNIVERSAL CARBOHYDRATE CONJUGATE VACCINE AGAINST GAS THAT ALLEVIATES AN OVERRIDING SAFETY CONCERN RELATED TO RHEUMATIC HEART DISEASE (RHD), A COMPLICATION OF GAS INFECTION AND A SIGNIFICANT CAUSE OF GLOBAL MORTALITY. TO FACILITATE THIS, THE ACADEMIC LABORATORY OF VICTOR NIZET, MD AT UC SAN DIEGO DISCOVERED THE GENETIC BASIS OF THE MOST ABUNDANT, UNIVERSALLY CONSERVED, SPECIES-DEFINING GAS CELL WALL CARBOHYDRATE ANTIGEN, AND A WAY TO MODIFY IT TO ELIMINATE AN EPITOPE THAT IS BELIEVED TO BE RESPONSIBLE FOR THE GENERATION OF CROSS-REACTIVE ANTIBODIES THAT CAN TARGET HUMAN CARDIAC OR BRAIN TISSUE BY KNOCKING OUT THE PATHWAY RESPONSIBLE FOR SYNTHESIS OF THE GLCNAC SIDE CHAIN. THIS PATENTED DISCOVERY PAVE THE WAY FOR USE OF THE MODIFIED €œPOLYRHAMNOSE€Ͽ½ ANTIGEN IN CONJUGATE VACCINE DEVELOPMENT FOR THE WORLD POPULATION, EXECUTED IN A COLLABORATION LEVERAGING THE UNIQUE XPRESSCF+TM PROTEIN EXPRESSION PLATFORM AND CONJUGATION TECHNOLOGY DEVELOPED BY VAXCYTE, A BIOTECHNOLOGY AND VACCINE COMPANY IN FOSTER CITY, CA, WHO OWNS AN EXCLUSIVE LICENSE FOR THE USE OF THE POLYRHAMNOSE CARBOHYDRATE THROUGH UC SAN DIEGO.
MANY CONSERVED SURFACE OR SECRETED VIRULENCE FACTORS INCLUDING C5A PEPTIDASE, SERINE PROTEASE SPYCEP, CYSTEINE PROTEASE SPEB, STREPTOLYSIN O (SLO), ARGININE DEIMINASE (ADI), PILUS ANTIGEN, FIBRONECTIN BINDING PROTEIN, HAVE SHOWN PROMISING RESULTS IN PRECLINICAL ANIMAL MODELS. MANY OF THE TARGETS WHICH ARE BEING INVESTIGATED HAVE YIELDS IN CONVENTIONAL SYSTEMS OF LESS THAN 10MG/L, WHICH IS NOT SUFFICIENT FOR A VACCINE. IN THE VAXCYTE SYSTEM, YIELDS OF THESE CANDIDATE ANTIGENS BETWEEN 10X-50X LITERATURE REPORTED YIELDS, CONFERRING A SIGNIFICANT ADVANTAGE TO OUR JOINT DEVELOPMENT EFFORT.
THE KEY DIFFERENTIATING FACTORS OF THE VAXCYTE/UCSD PROGRAM ARE 1) POLYSACCHARIDE CONJUGATE ANTIGENS CONTAINING ONLY THE POLY-RHAMNOSE AND NOT GLCNAC, 2) SITE-SPECIFIC CONJUGATION OF THESE POLYSACCHARIDES TO AN IMMUNOGENIC PROTEIN CARRIER, AND 3) GENERATION OF CROSS-LINKED POLYSACCHARIDE-CONJUGATES. FURTHERMORE, THE YIELD OF PROTEINS INCLUDED IN THE VACCINE IS SIGNIFICANTLY HIGHER IN THE VAXCYTE SYSTEM, DECREASING THE COST OF GOODS ON THE FINAL VACCINE THAT IS IMPORTANT FOR A VACCINE THAT HAS SUCH A POTENTIAL IMPACT ON MORBIDITY AND MORTALITY IN THE DEVELOPING WORLD. THUS, UTILIZING THE TECHNOLOGY AND THE UNIQUE CAPABILITIES OF THIS COLLABORATION, A PRECISELY CHARACTERIZED AND CONSISTENTLY PRODUCED FIRST-IN-CLASS SAFE AND BROADLY PROTECTIVE VACCINE AGAINST GAS INFECTIONS CAN BE SUCCESSFULLY PRODUCED AT INDUSTRIAL SCALE FOR USE IN HUMAN POPU 4500004430 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | -$396,694 | Jan 26, 2023 | — – — |
| Subcontractor | Department of Health and Human Services | GROUP A STREPTOCOCCUS OR GAS (STREPTOCOCCUS PYOGENES) IS A HUMAN PATHOGEN CAUSING 700 MILLION CASES OF PHARYNGITIS (€ˌSTREP THROAT€„¢) ANNUALLY WORLDWIDE WHILE CDC ESTIMATES APPROXIMATELY 11,000 TO 13,000 CASES OF INVASIVE GAS DISEASE OCCUR EACH YEAR IN THE UNITED STATES ALONE FROM WHICH, BETWEEN 1,100 AND 1,600 PEOPLE DIE. OVERALL, €ˌSTREP THROAT€„¢ IS HIGHLY PREVALENT IN SCHOOL-AGE CHILDREN AND A SIGNIFICANT SOURCE OF ANTIBIOTIC PRESCRIPTION WORLDWIDE, DRIVING SELECTIVE PRESSURE FOR RESISTANCE THROUGHOUT THE HUMAN MICROFLORA. FURTHERMORE, GAS IS ALSO RESPONSIBLE FOR POST-INFECTIOUS IMMUNE-MEDIATED RHEUMATIC HEART DISEASE (RHD), A LEADING CAUSE OF MORTALITY IN THE DEVELOPING WORLD. SOME 30 MILLION PEOPLE ARE CURRENTLY AFFECTED BY RHD, WITH OVER 420,000 DEATHS ANNUALLY (60% < AGE 70) AND 11.5 MILLION DISABILITY-ADJUSTED LIFE YEARS LOST. DESPITE THE HIGH GLOBAL DEMAND, THERE IS NO SAFE AND EFFECTIVE VACCINE AGAINST GAS. THE WORLD HEALTH ORGANIZATION, INTERNATIONAL VACCINE INSTITUTE, WELLCOME TRUST, GATES FOUNDATION, AND OTHERS HAVE CONVENED ADVISORIES ON GAS VACCINE DEVELOPMENT TO ADDRESS THESE SIGNIFICANT SCIENTIFIC CHALLENGES AND MEET THIS PARAMOUNT GLOBAL HEALTH NEED. TO ACHIEVE THIS GOAL AND TO GENERATE A SAFE, ECONOMICAL AND EFFECTIVE VACCINE AGAINST GAS INFECTIONS, THE TEAMS AT VAXCYTE AND NIZET LAB (UCSD) ARE COLLABORATING TO UTILIZE THEIR TECHNOLOGICAL EXPERTISE TO DEVELOP A UNIVERSAL CARBOHYDRATE CONJUGATE VACCINE AGAINST GAS THAT ALLEVIATES AN OVERRIDING SAFETY CONCERN RELATED TO RHEUMATIC HEART DISEASE (RHD), A COMPLICATION OF GAS INFECTION AND A SIGNIFICANT CAUSE OF GLOBAL MORTALITY. TO FACILITATE THIS, THE ACADEMIC LABORATORY OF VICTOR NIZET, MD AT UC SAN DIEGO DISCOVERED THE GENETIC BASIS OF THE MOST ABUNDANT, UNIVERSALLY CONSERVED, SPECIES-DEFINING GAS CELL WALL CARBOHYDRATE ANTIGEN, AND A WAY TO MODIFY IT TO ELIMINATE AN EPITOPE THAT IS BELIEVED TO BE RESPONSIBLE FOR THE GENERATION OF CROSS-REACTIVE ANTIBODIES THAT CAN TARGET HUMAN CARDIAC OR BRAIN TISSUE BY KNOCKING OUT THE PATHWAY RESPONSIBLE FOR SYNTHESIS OF THE GLCNAC SIDE CHAIN. THIS PATENTED DISCOVERY PAVE THE WAY FOR USE OF THE MODIFIED €œPOLYRHAMNOSE€Ͽ½ ANTIGEN IN CONJUGATE VACCINE DEVELOPMENT FOR THE WORLD POPULATION, EXECUTED IN A COLLABORATION LEVERAGING THE UNIQUE XPRESSCF+TM PROTEIN EXPRESSION PLATFORM AND CONJUGATION TECHNOLOGY DEVELOPED BY VAXCYTE, A BIOTECHNOLOGY AND VACCINE COMPANY IN FOSTER CITY, CA, WHO OWNS AN EXCLUSIVE LICENSE FOR THE USE OF THE POLYRHAMNOSE CARBOHYDRATE THROUGH UC SAN DIEGO. MANY CONSERVED SURFACE OR SECRETED VIRULENCE FACTORS INCLUDING C5A PEPTIDASE, SERINE PROTEASE SPYCEP, CYSTEINE PROTEASE SPEB, STREPTOLYSIN O (SLO), ARGININE DEIMINASE (ADI), PILUS ANTIGEN, FIBRONECTIN BINDING PROTEIN, HAVE SHOWN PROMISING RESULTS IN PRECLINICAL ANIMAL MODELS. MANY OF THE TARGETS WHICH ARE BEING INVESTIGATED HAVE YIELDS IN CONVENTIONAL SYSTEMS OF LESS THAN 10MG/L, WHICH IS NOT SUFFICIENT FOR A VACCINE. IN THE VAXCYTE SYSTEM, YIELDS OF THESE CANDIDATE ANTIGENS BETWEEN 10X-50X LITERATURE REPORTED YIELDS, CONFERRING A SIGNIFICANT ADVANTAGE TO OUR JOINT DEVELOPMENT EFFORT. THE KEY DIFFERENTIATING FACTORS OF THE VAXCYTE/UCSD PROGRAM ARE 1) POLYSACCHARIDE CONJUGATE ANTIGENS CONTAINING ONLY THE POLY-RHAMNOSE AND NOT GLCNAC, 2) SITE-SPECIFIC CONJUGATION OF THESE POLYSACCHARIDES TO AN IMMUNOGENIC PROTEIN CARRIER, AND 3) GENERATION OF CROSS-LINKED POLYSACCHARIDE-CONJUGATES. FURTHERMORE, THE YIELD OF PROTEINS INCLUDED IN THE VACCINE IS SIGNIFICANTLY HIGHER IN THE VAXCYTE SYSTEM, DECREASING THE COST OF GOODS ON THE FINAL VACCINE THAT IS IMPORTANT FOR A VACCINE THAT HAS SUCH A POTENTIAL IMPACT ON MORBIDITY AND MORTALITY IN THE DEVELOPING WORLD. THUS, UTILIZING THE TECHNOLOGY AND THE UNIQUE CAPABILITIES OF THIS COLLABORATION, A PRECISELY CHARACTERIZED AND CONSISTENTLY PRODUCED FIRST-IN-CLASS SAFE AND BROADLY PROTECTIVE VACCINE AGAINST GAS INFECTIONS CAN BE SUCCESSFULLY PRODUCED AT INDUSTRIAL SCALE FOR USE IN HUMAN POPULAT 4500004430 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $696,694 | Nov 9, 2022 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.
Government-sourced data comes from SAM.gov, SBA and USAspending.gov and is attributed to its source. Items marked company-reported were provided by the company and are verified by FedSub only where labeled. FedSub is a private company and is not affiliated with SBA, GSA/SAM.gov, or any government agency.